BACKGROUND: Trefoil peptides (TFF-1, 2, 3) are a family of protease-resistant regulatory factors that play a role in mucosal restitution, angiogenesis, apoptosis, and tumor progression. Intestinal trefoil peptide (TFF-3) expression has been demonstrated in benign hepatobiliary diseases, but there are limited data regarding its expression in HCC. METHODS: Thirty consecutive cases of HCC from 1998 to 2003 were studied. Immunohistochemistry was performed on formalin-fixed paraffin-embedded blocks of HCC using polyclonal antibody to TFF-3. TFF-3 expression was classified as strong, moderate, weak, focal, and negative. Clinical data were obtained per an IRB-approved protocol. RESULTS: Median age was 69 yr (range: 39-83 yr). Twenty- three patients were males and 7 were females. Treatments included hepatic resection (n = 16), chemo-embolization (n = 4), combined modality therapy (n = 5) and no treatment (n = 4). HCC was well differentiated in 12 (40%), moderately differentiated in 13 (43%), and poorly differentiated in 5 (17%) patients. TFF-3 expression was detected in 28/30 (93.3%) patient samples. Sixteen patients (53%) had moderate and 1 (3%) patient had strong TFF-3 expression. Tumor/ normal tissue interface was assessable in 21 cases; 11 cases expressed TFF-3 at the interface. There was a strong correlation between tumor grade and TFF-3 expression, wherein poorly differentiated tumors had moderate/strong TFF-3 expression (p = 0.008). There was no correlation between TFF-3 expression and survival (p = 0.77). Furthermore, there was no correlation among age, disease stage, and survival. CONCLUSION: TFF-3 is commonly expressed in HCC and its expression correlates with tumor grade.
BACKGROUND: Trefoil peptides (TFF-1, 2, 3) are a family of protease-resistant regulatory factors that play a role in mucosal restitution, angiogenesis, apoptosis, and tumor progression. Intestinal trefoil peptide (TFF-3) expression has been demonstrated in benign hepatobiliary diseases, but there are limited data regarding its expression in HCC. METHODS: Thirty consecutive cases of HCC from 1998 to 2003 were studied. Immunohistochemistry was performed on formalin-fixed paraffin-embedded blocks of HCC using polyclonal antibody to TFF-3. TFF-3 expression was classified as strong, moderate, weak, focal, and negative. Clinical data were obtained per an IRB-approved protocol. RESULTS: Median age was 69 yr (range: 39-83 yr). Twenty- three patients were males and 7 were females. Treatments included hepatic resection (n = 16), chemo-embolization (n = 4), combined modality therapy (n = 5) and no treatment (n = 4). HCC was well differentiated in 12 (40%), moderately differentiated in 13 (43%), and poorly differentiated in 5 (17%) patients. TFF-3 expression was detected in 28/30 (93.3%) patient samples. Sixteen patients (53%) had moderate and 1 (3%) patient had strong TFF-3 expression. Tumor/ normal tissue interface was assessable in 21 cases; 11 cases expressed TFF-3 at the interface. There was a strong correlation between tumor grade and TFF-3 expression, wherein poorly differentiated tumors had moderate/strong TFF-3 expression (p = 0.008). There was no correlation between TFF-3 expression and survival (p = 0.77). Furthermore, there was no correlation among age, disease stage, and survival. CONCLUSION:TFF-3 is commonly expressed in HCC and its expression correlates with tumor grade.
Authors: Takasuke Yamachika; J Lawrence Werther; Carol Bodian; Mark Babyatsky; Masae Tatematsu; Yoshitaka Yamamura; Anli Chen; Steven Itzkowitz Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: R Parasole; F Izzo; F Perrone; S Pignata; M G Galati; E Leonardi; F Castiglione; R Orlando; G Castello; G Esposito; C Gallo; B Daniele Journal: Clin Cancer Res Date: 2001-11 Impact factor: 12.531
Authors: Mark J Hoenerhoff; Arun R Pandiri; Stephanie A Lahousse; Hu-Hua Hong; Tai-Vu Ton; Tiwanda Masinde; Scott S Auerbach; Kevin Gerrish; Pierre R Bushel; Keith R Shockley; Shyamal D Peddada; Robert C Sills Journal: Toxicol Pathol Date: 2011-05-13 Impact factor: 1.902
Authors: Julie M Kneller; Thomas Ehlen; Jasenka P Matisic; Dianne Miller; Dirk Van Niekerk; Wan L Lam; Marco Marra; Rebecca Richards-Kortum; Michelle Follen; Calum Macaulay; Steven J M Jones Journal: Biomark Insights Date: 2007-12-11
Authors: Vijay Pandey; Min Zhang; Qing-Yun Chong; Mingliang You; Ainiah Rushdiana Raquib; Amit K Pandey; Dong-Xu Liu; Liang Liu; Lan Ma; Sudhakar Jha; Zheng-Sheng Wu; Tao Zhu; Peter E Lobie Journal: Oncotarget Date: 2017-08-24